Literature DB >> 20033065

Inhibitory efficacy of hypoxia-inducible factor 1alpha short hairpin RNA plasmid DNA-loaded poly (D, L-lactide-co-glycolide) nanoparticles on choroidal neovascularization in a laser-induced rat model.

C Zhang1, Y-S Wang, H Wu, Z-X Zhang, Y Cai, H-Y Hou, W Zhao, X-M Yang, J-X Ma.   

Abstract

The aim of this study was to evaluate the possibility of poly (D, L-lactide-co-glycolide) nanoparticle (NPs) as a gene vector for functional plasmid DNA (pDNA) and to investigate its inhibitory efficacy on experimental choroidal neovascularization (CNV). We developed intravitreal administered, hypoxia-inducible factor 1alpha (HIF-1alpha) short hairpin RNA and green fluorescent protein (GFP) co-expressed pDNA-loaded NPs (pshHIF-1alpha NPs). CNV was induced by laser photocoagulation in 112 rats. The rats were then randomly assigned to be injected intravitreally with phosphate-buffered saline (PBS), blank NPs, naked pDNA, control pDNA NPs and pshHIF-1alpha NPs, respectively, and non-injection group was set as the control. Immunofluorescence staining, fluorescein fundus angiography and histologic analysis were performed to evaluate the inhibitory efficacy on CNV. The results showed that the expression of GFP preferentially localized in the retinal pigment epithelium cell layer and lasted for 4 weeks. The fluorescein leakage areas of CNV were significantly larger in the PBS, blank NPs, control pDNA NPs, non-injection group and naked pDNA group than in pshHIF-1alpha NPs group (P<0.01). The mean thickness of the CNV lesions in the intravitreally pshHIF-1alpha NPs-treated group was significantly smaller than other groups (P<0.01). No signs of functional or ultrastructural destruction in retina were detected. Therefore, pshHIF-1alpha NPs may act as a novel therapeutic option to transfer specific pDNA and inhibit the formation of experimental CNV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20033065     DOI: 10.1038/gt.2009.158

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  16 in total

Review 1.  Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes.

Authors:  Rammohan Devulapally; Ramasamy Paulmurugan
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-08-31

2.  Retinal angiogenesis suppression through small molecule activation of p53.

Authors:  Sai H Chavala; Younghee Kim; Laura Tudisco; Valeria Cicatiello; Till Milde; Nagaraj Kerur; Nidia Claros; Susan Yanni; Victor H Guaiquil; William W Hauswirth; John S Penn; Shahin Rafii; Sandro De Falco; Thomas C Lee; Jayakrishna Ambati
Journal:  J Clin Invest       Date:  2013-09-09       Impact factor: 14.808

3.  Comparative study of laser-induced choroidal neovascularization in rats by paraffin sections, frozen sections and high-resolution optical coherence tomography.

Authors:  Jian Jiao; Bin Mo; Hang Wei; Yan-rong Jiang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-23       Impact factor: 3.117

Review 4.  Nanoparticle-motivated gene delivery for ophthalmic application.

Authors:  Rajendra Narayan Mitra; Min Zheng; Zongchao Han
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-06-22

Review 5.  Polymeric vectors for ocular gene delivery.

Authors:  Viral Tamboli; Gyan P Mishra; Ashim K Mitrat
Journal:  Ther Deliv       Date:  2011-04

Review 6.  Nanoengineering of therapeutics for retinal vascular disease.

Authors:  Nivriti Gahlaut; Sandra Suarez; Md Imam Uddin; Andrew Y Gordon; Stephanie M Evans; Ashwath Jayagopal
Journal:  Eur J Pharm Biopharm       Date:  2015-05-28       Impact factor: 5.571

Review 7.  Nanoparticle-based technologies for retinal gene therapy.

Authors:  Jeffrey Adijanto; Muna I Naash
Journal:  Eur J Pharm Biopharm       Date:  2015-01-12       Impact factor: 5.571

Review 8.  Gene delivery nanoparticles to modulate angiogenesis.

Authors:  Jayoung Kim; Adam C Mirando; Aleksander S Popel; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2016-11-30       Impact factor: 15.470

9.  Lentivirus vector-mediated knockdown of erythropoietin-producing hepatocellular carcinoma receptors B4 inhibits laser-induced choroidal neovascularization.

Authors:  Jing Du; Wei Zhao; Yusheng Wang; Yan Cai
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-04       Impact factor: 2.671

10.  Cell-specific gene therapy driven by an optimized hypoxia-regulated vector reduces choroidal neovascularization.

Authors:  Manas R Biswal; Howard M Prentice; George W Smith; Ping Zhu; Yao Tong; C Kathleen Dorey; Alfred S Lewin; Janet C Blanks
Journal:  J Mol Med (Berl)       Date:  2018-08-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.